ArticleFrontiers in immunology2023

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States.

Wentao Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.